Enovis (NYSE:ENOV) Stock: Insider Sharon Wienbar Buys 900 Shares

Key Points

• Enovis director Sharon Wienbar bought 900 shares for $24,984 at an average price of $27.76, increasing her stake by 2.02% to 45,551 shares.
• Enovis beat quarterly estimates, reporting EPS of $0.88 versus $0.77 expected and revenue of $558.73 million, up 1.8% year over year.
• Analysts give the stock a Moderate Buy consensus rating with an average price target of $38.62; shares traded at $27.63 in Thursday’s midday session.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Sharon Wienbar acquired 900 shares of Enovis stock in a transaction that occurred on Wednesday, November 11th. The stock was acquired at an average price of $27.76 per share, with a total value of $24,984.00. Following the completion of the acquisition, the director directly owned 45,551 shares in the company, valued at $1,264,495.76. This represents a 2.02% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Enovis Stock Performance

ENOV traded down $0.92 during midday trading on Thursday, hitting $27.63. 1,153,270 shares of the company traded hands, compared to its average volume of 1,886,113. The firm has a market capitalization of $1.59 billion, a PE ratio of -3.00 and a beta of 1.31. The company's 50-day moving average is $20.36 and its 200 day moving average is $23.19. Enovis Corporation has a 52 week low of $16.70 and a 52 week high of $31.81. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82.

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The company had revenue of $558.73 million for the quarter, compared to analysts' expectations of $557.12 million. During the same quarter last year, the company posted $0.75 earnings per share. The firm's quarterly revenue was up 1.8% on a year-over-year basis. On average, research analysts expect that Enovis Corporation will post 3.15 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ENOV. Wells Fargo & Company increased their price target on Enovis from $33.00 to $37.00 and gave the company an "overweight" rating in a report on Friday, November 6th. Weiss Ratings raised Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 2nd. UBS Group reaffirmed a "buy" rating and issued a $44.00 price objective on shares of Enovis in a report on Monday, October 5th. Citigroup reiterated a "market outperform" rating on shares of Enovis in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC increased their target price on Enovis from $34.00 to $38.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Enovis has an average rating of "Moderate Buy" and an average price target of $38.62.

Hedge Funds Weigh In On Enovis

Institutional investors and hedge funds have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY grew its position in Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock valued at $40,420,000 after buying an additional 732,917 shares during the period. Private Management Group Inc. raised its position in Enovis by 31.3% in the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company's stock worth $32,748,000 after acquiring an additional 427,347 shares during the period. Allspring Global Investments Holdings LLC raised its position in Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock worth $24,430,000 after acquiring an additional 287,687 shares during the period. Front Street Capital Management Inc. raised its position in Enovis by 106.1% in the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company's stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP boosted its stake in shares of Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company's stock worth $13,752,000 after acquiring an additional 342,556 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.